MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine
- 19 June 2015
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 32 (7) , 1-9
Abstract
Genetic alterations in the PI3K/AKT cascade have been linked to various human cancers including acute myeloid leukemia (AML) and have emerged to be promising targets for treatment. In this study, we explored the molecular mechanism and clinical implication of a specific allosteric AKT inhibitor, MK-2206, in the treatment of AML. Four leukemia cell lines, MV-4-11, MOLM-13, OCI/AML3, and U937, were used. Apoptosis and cell cycle distribution were determined by flow cytometry analysis. Expression of anti-apoptotic protein family and glycogen synthase kinase 3β (GSK3β) signaling was determined by western blotting. Drug combination effects of MK-2206 with cytarabine were evaluated by cell proliferation assay, and the combination index values were calculated by CompuSyn software. MK-2206 had no effect on normal peripheral blood mononuclear cells, but induced G1-phase arrest and apoptosis in leukemia cells. Among anti-apoptotic Bcl-2 family members, only myeloid cell leukemia-1 (Mcl-1) was significantly suppressed. Mcl-1 suppression by MK-2206 was closely associated with decreased GSK3β phosphorylation at Ser9, an event leads to GSK3β activation. Furthermore, the effect of MK-2206 on Mcl-1 downregulation was abolished by GSK3β inhibitor, lithium chloride and proteasome inhibitor, MG-132, suggesting that MK-2206 acted through a GSK3β-mediated, proteasome-dependent protein degradation. In addition, co-administration of MK-2206 with cytarabine could enhance the cytotoxic efficacy of cytarabine in leukemia cell lines. In conclusion, we have demonstrated that MK-2206 is an active agent in AML and its efficacy as in combination with cytarabine is implicated.Keywords
Funding Information
- National Science Council Taiwan (NSC 99-2320-B-002-018-MY3)
- National Taiwan University Hospital (NTUH.101-S1833)
- National Science Council Taiwan (NSC 100-2320-B-002-074-MY3)
This publication has 44 references indexed in Scilit:
- Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor PathwayPLOS ONE, 2013
- Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapiesBlood Cancer Journal, 2012
- Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinomaThe Laryngoscope, 2011
- The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt PathwayThe Journal of Clinical Endocrinology & Metabolism, 2011
- eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206Cancer Research, 2011
- Identification of Predictive Markers of Cytarabine Response in AML by Integrative Analysis of Gene-Expression Profiles with Multiple PhenotypesPharmacogenomics, 2011
- The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathwaysBlood, 2009
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- Degradation of Mcl-1 by β-TrCP Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and ChemosensitizationMolecular and Cellular Biology, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001